Advancements in AL Amyloidosis Treatment

The Andromeda trial has marked a significant breakthrough in the treatment of AL amyloidosis with the introduction of daratumumab combined with VCD (DARA-VCD) as a new standard of care. This trial demonstrated that 59% of patients treated with DARA-VCD achieved complete hematologic response compared to only 19% of those receiving VCD alone, indicating a much higher efficacy. Furthermore, the findings indicated improved overall survival and reduced organ deterioration, underscoring the treatment's effectiveness over traditional methods. The results from five years of follow-up suggest that this approach is set to replace autologous stem cell transplant, proving to be a well-tolerated option that enhances patient outcomes.